ID: h-ca6480add4
Hypothesis
Physiological SCFAs may confer indirect anti-synuclein benefit through an enteroendocrine FFAR2/FFAR3 to GLP-1 axis
At realistic exposure levels, SCFAs are more likely to act as receptor-mediated endocrine signals than as direct neuronal epigenetic modulators.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
At realistic exposure levels, SCFAs are more likely to act as receptor-mediated endocrine signals than as direct neuronal epigenetic modulators. Activation of intestinal FFAR2/FFAR3 on L cells could raise GLP-1 signaling and secondarily improve neuronal stress resistance or proteostasis, but the current evidence supports mediation plausibility more than proven alpha-synuclein clearance.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["FFAR2/GPR43<br/>High SCFA Affinity Receptor"]
B["Acetate-Driven Activation<br/>G-protein Coupling"]
C["PI3K/AKT Pathway<br/>Anti-apoptotic Signaling"]
D["NLRP3 Inhibition<br/>Anti-inflammatory Effect"]
E["Microglial Homeostasis<br/>M2 Polarization"]
F["Gut Microbiome Dysbiosis<br/>SCFA Depletion"]
G["Synaptic Integrity<br/>Support of Neuronal Function"]
H["Neuroinflammation<br/>Pro-inflammatory Shift"]
I["Cognitive Decline<br/>AD and Related Dementias"]
A --> B
B --> C
C --> D
D --> E
E --> G
F --> H
H --> I
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style I fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix3 supports2 contradicts
Supports
SCFAs are established ligands for GPR41/GPR43, providing a plausible receptor-level mechanism at physiologic concentrations.
Supports
Butyrate-associated benefit in PD models has been linked with increased GLP-1 signaling, supporting an indirect endocrine pathway.
Supports
A rotenone model showed sodium butyrate benefit alongside GLP-1-related changes, consistent with but not proving mediation.
Contradicts
Available studies used pharmacologic sodium butyrate and do not demonstrate that physiologic micromolar exposure is sufficient for meaningful alpha-synuclein clearance.
Contradicts
Low circulating SCFA levels and compartment differences make translational dose matching uncertain.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — FFAR2
No curated PDB or AlphaFold mapping for FFAR2 yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for FFAR2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.3%
Volatility
Medium
0.0227
Events (7d)
2
Price History
▼18.5%💾 Resource Usage
LLM Tokens
19,114
$0.0573
Total Cost
$0.0573
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF FFAR2/FFAR3 signaling is selectively blocked in intestinal L cells using a pharmacological antagonist (e.g., CATPB for FFAR2) or Cre-lox L cell-specific FFAR2/FFAR3 knockout, THEN GLP-1 plasma leve | Decrease in plasma active GLP-1 (GLP-1 7-36 amide) by >40% and no reduction or increase in pS129-αSyn burden in ventral striatum and enteric neurons; motor defi | — no observation — | pending | 0.35 |
| IF germ-free Thy1-αSyn mice are colonized with a defined consortium of acetate- and propionate-producing human gut bacteria (e.g., Blautia producta, Bacteroides thetaiotaomicron at 1e8 CFU each, biwee | Significant elevation in plasma GLP-1 (ELISA) and improvement in behavioral metrics (grid walk, cylinder test) with stereological evidence of reduced neuronal a | — no observation — | pending | 0.40 |
🔮 Falsifiable Predictions (2)
pendingconf 40%
IF germ-free Thy1-αSyn mice are colonized with a defined consortium of acetate- and propionate-producing human gut bacteria (e.g., Blautia producta, Bacteroides thetaiotaomicron at 1e8 CFU each, biweekly oral gavage), THEN plasma GLP-1 levels will increase by >50% and motor impairment (grid walk fai
Predicted outcome: Significant elevation in plasma GLP-1 (ELISA) and improvement in behavioral metrics (grid walk, cylinder test) with stereological evidence of reduced
Falsification: If GLP-1 does not rise >50% or motor deficits persist despite SCFA-producing microbiota colonization, the enteroendocrine axis does not mediate the neuroprotective effect.
pendingconf 35%
IF FFAR2/FFAR3 signaling is selectively blocked in intestinal L cells using a pharmacological antagonist (e.g., CATPB for FFAR2) or Cre-lox L cell-specific FFAR2/FFAR3 knockout, THEN GLP-1 plasma levels will decrease by >40% and alpha-synuclein pathology burden will not decrease but rather increase
Predicted outcome: Decrease in plasma active GLP-1 (GLP-1 7-36 amide) by >40% and no reduction or increase in pS129-αSyn burden in ventral striatum and enteric neurons;
Falsification: If GLP-1 levels are unchanged or if alpha-synuclein pathology still decreases despite FFAR2/FFAR3 blockade, the enteroendocrine axis is not the primary mechanism and the hypothesis is falsified.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.